Fosmanogepix

Fosmanogepix is an experimental antifungal drug being developed by Amplyx Pharmaceuticals (now currently by Pfizer and Basilea )  It is being investigated for its potential to treat various fungal infections including aspergillosis, candidaemia, and coccidioidomycosis.

Fosmanogepix is a prodrug and is converted into the active drug form, manogepix in vivo. Manogepix targets the enzyme GWT1 (Glycosylphosphatidylinositol-anchored Wall protein Transfer 1 ), an enzyme in the glycosylphosphatidylinositol biosynthesis pathway. Inhibiting this enzyme prevents the fungi from properly modifying certain (so called GPI-anchored) proteins essential to the fungal life cycle. This mechanism of action is totally novel; therefore, if approved, fosmanogepix would become a first-in-class medication.

In 2023, the drug was given a compassionate use authorization for four patients with Fusarium solani meningitis.